Non-Invasive Prenatal Testing Market to Register a Stout Growth by End 2027

Posted by Rohini Chaudhari on February 10th, 2020

  • Transparency Market Research (TMR) has published a new report titled, “Non-Invasive Prenatal Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”.According to the report, the global non-invasive prenatal testing market was valued at US$ 1300 Mn in 2018. It is projected to expand at a CAGR of 16% from 2019 to 2027.
  • Increasing cases of Downs’ syndrome, rising maternal age, and increasing demand for early and non-invasive fetal testing procedures are anticipated to boost the global non-invasive prenatal testing market from 2019 to 2027.
  • Stringent regulatory guidelines, limitations of non-invasive prenatal testing, and availabilities of other alternatives would likely to hamper the growth of the global non-invasive prenatal testing market in the future.
  • On the other, emerging non-invasive prenatal testing will prove an opportunity to the global non-invasive prenatal testing market in the upcoming future.
  • North America is expected to dominate the global non-invasive prenatal testing market in the next few years, while the non-invasive prenatal testing market in Asia Pacific is likely to propel at a significant growth rate in the near future.

Planning To Lay Down Future Strategy? Request Brochure Of Non-Invasive Prenatal Testing Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=374

Materni21 segment to hold prominent market share

  • Based on test type, the global non-invasive prenatal testing market has been classified into Materni21, Harmony, Panorama, Verifi, NIFTY, and others.
  • The MaterniT21 segment accounted for a significant share of the global non-invasive prenatal testing market in 2018. The segment is estimated to remain highly lucrative during the forecast period.
  • In the U.S,, Sequenom (which was presently a part of Labcorp) introduced MateriT21 in 2011, which was the first NIPT solution in the U.S. MaterniT21 is able to identify trisomies and expanded tests may also explain sex chromosomes disabilities and some microdeletions. Less percentage error is a significant advantage of MaterniT21.
  • In addition to MaternitT21, the Panorama segment held a notable share of the global non-invasive prenatal testing market, in terms of volume, in 2018.

Like it? Share it!


Rohini Chaudhari

About the Author

Rohini Chaudhari
Joined: June 12th, 2019
Articles Posted: 205

More by this author